Akoya Biosciences, Inc.
AKYA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $113 | $217 | $361 | $573 |
| - Cash | $12 | $83 | $74 | $113 |
| + Debt | $84 | $86 | $76 | $33 |
| Enterprise Value | $186 | $219 | $363 | $493 |
| Revenue | $82 | $97 | $75 | $55 |
| % Growth | -15.5% | 29.1% | 36.3% | – |
| Gross Profit | $48 | $56 | $43 | $34 |
| % Margin | 58.6% | 58.3% | 58% | 62.3% |
| EBITDA | -$37 | -$46 | -$59 | -$35 |
| % Margin | -45.5% | -47.2% | -78.6% | -64% |
| Net Income | -$55 | -$63 | -$71 | -$43 |
| % Margin | -67.8% | -65.5% | -94.4% | -78.2% |
| EPS Diluted | -1.12 | -1.43 | -1.87 | -1.19 |
| % Growth | 21.7% | 23.5% | -57.1% | – |
| Operating Cash Flow | -$44 | -$51 | -$53 | -$36 |
| Capital Expenditures | -$2 | -$4 | -$7 | -$5 |
| Free Cash Flow | -$47 | -$55 | -$61 | -$41 |